TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Investor Investigation Over Potential Securities Laws Violations Announced

  • If you purchased shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT), you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

Company
Conatus Pharmaceuticals Inc
Security
NASDAQ: CNAT

Summary

March 9, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) shares over potential securities laws violations by Conatus Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) concerning whether a series of statements by Conatus Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On March 5, 2015, Conatus Pharmaceuticals Inc disclosed that on March 2, 2015, Gary C. Burgess, M.B., Ch.B. M.Med., tendered his resignation as Senior Vice President, Clinical Research and Chief Medical Officer of Conatus Pharmaceuticals Inc., effective April 2, 2015. Shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) declined to as low as $5.61 per share on March 6, 2015.

Start Monitoring Your Investments